Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-067237
Filing Date
2024-08-09
Accepted
2024-08-09 17:24:00
Documents
15
Period of Report
2024-08-05
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0211021-8ka_bioessence.htm   iXBRL 8-K/A 26768
2 LETTER FROM FORMER AUDITOR ea021102101ex99-1_bio.htm EX-99.1 3396
3 GRAPHIC ex99-1_001.jpg GRAPHIC 21092
  Complete submission text file 0001213900-24-067237.txt   230975

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bioe-20240805.xsd EX-101.SCH 3033
5 XBRL LABEL FILE bioe-20240805_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE bioe-20240805_pre.xml EX-101.PRE 22371
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0211021-8ka_bioessence_htm.xml XML 3448
Mailing Address 12 CHRYSLER UNIT B IRVINE CA 92618
Business Address 12 CHRYSLER UNIT B IRVINE CA 92618 949-706-9966
Bio Essence Corp (Filer) CIK: 0001723059 (see all company filings)

EIN.: 943349551 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-56263 | Film No.: 241194094
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)